drugset / Trial / NCT00154843

A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation

NCT00154843

Phase 2 Completed 74 enrolled National Taiwan University Hospital
RandomizedParallel-groupOpen-labelPrevention

Summary

Primary: To determine factors that affect absorption and serum levels of lycopene after supplementation. Secondary: 1. To evaluate general safety and tolerability of oral lycopene 15 or 30 mg per day for 12 weeks. 2. To determine lycopene effects on reducing serum levels of prostate specific antigen (PSA) and on relieving lower urinary tract symptoms (LUTS) in relation to prostate hypertrophy as evaluated by the International Prostate Symptom Score (I-PSS).

Timeline

Start
2004-03
Primary completion
2005-06
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Lycopene Other / unclassified 15 mg Oral
Subject Lycopene Other / unclassified 30 mg Oral